Edit
Remedy Pharmaceuticals, Inc.
http://www.remedypharmaceuticals.com/Last activity: 03.09.2024
Active
Remedy Pharmaceuticals, Inc., located in New York City, is a late-stage specialty pharma focused on therapies capable of transforming treatment in the management of life-threatening brain edema-related conditions − where there are inadequate or no approved existing therapies.
CNS-related edema (swelling) is a large unmet medical need that carries significant mortality, morbidity and societal burdens. Solve the problem of edema and you have taken the biggest step forward in the history of treating these patients.
How large is this opportunity? For instance, there are 110,000 LHIs in the U.S. each year. CNS-related edema is present in multiple critical care indications, i.e., LHI, subarachnoid hemorrhage, intracerebral hemorrhage, traumatic brain injury, cardiac arrest, spinal cord injury, etc., as well as in chronic conditions such as brain tumors (primary and metastases).
For more information, go to:http://www.remedypharmaceuticals.com
CNS-related edema (swelling) is a large unmet medical need that carries significant mortality, morbidity and societal burdens. Solve the problem of edema and you have taken the biggest step forward in the history of treating these patients.
How large is this opportunity? For instance, there are 110,000 LHIs in the U.S. each year. CNS-related edema is present in multiple critical care indications, i.e., LHI, subarachnoid hemorrhage, intracerebral hemorrhage, traumatic brain injury, cardiac arrest, spinal cord injury, etc., as well as in chronic conditions such as brain tumors (primary and metastases).
For more information, go to:http://www.remedypharmaceuticals.com
Location: United States, New York
Employees: 11-50
Total raised: $9M
Founded date: 2004
Investors 1
| Date | Name | Website |
| - | UM Venture... | umventures... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.12.2015 | - | $9M | - |
Mentions in press and media 4
| Date | Title | Description |
| 03.09.2024 | Remedy Pharmaceuticals Announces Further Analyses from Phase 3 Study Reveals CIRARA Could Significantly Improve Independent Ambulation in Large Hemispheric Infarction Patients | NEW YORK, Sept. 3, 2024 /PRNewswire/ -- Remedy Pharmaceuticals today announced promising new data from the Phase 3 CHARM clinical trial of CIRARA (IV glyburide) in Large Hemispheric Infarction (LHI), the most serious form of ischemic stroke... |
| 29.05.2024 | Remedy Pharmaceuticals Gets Rights To Acute Stroke Drug Back From Biogen; Announces Clinically Meaningful and Statistically Significant Results From Pre-specified Subgroup and Post Hoc Analyses of Pha... | NEW YORK, May 29, 2024 /PRNewswire/ -- Remedy Pharmaceuticals, a pioneer in stroke drug development, announced that prespecified subgroup analyses from the Phase 3 CHARM clinical trial of CIRARA (IV glibenclamide) showed meaningful improvem... |
| 01.12.2015 | Remedy Pharmaceuticals Completes $9M Financing Round | Remedy Pharmaceuticals, a NYC-based clinical stage pharmaceutical company focused on the development and commercialization of CIRARA™, a drug for severe stroke, completed a $9m financing round. Backers included new investors Vertical GP-5, ... |
| 10.02.2014 | Remedy Pharmaceuticals Receives Investment from Broadview Ventures | Remedy Pharmaceuticals, a New York City-based clinical stage pharmaceutical company, received an investment from Broadview Ventures. The amount of the deal was not disclosed. The company intends to use the funds to accelerate its GAMES-RP c... |